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Background: The success of 7-valent pneumococcal conjugate vaccination (PCV-7) introduced to the US childhood
immunization schedule in 2000 was partially offset by increases in invasive pneumococcal disease (IPD) and
pneumococcal carriage due to non-vaccine serotypes, in particular 19A, in the years that followed. A 13-valent conjugate
vaccine (PCV-13) was introduced in 2010. As part of an ongoing study of the response of the Massachusetts pneumococcal
population to conjugate vaccination, we report the findings from the samples collected in 2011, as PCV-13 was introduced.
Methods: We used multilocus sequence typing (MLST) to analyze 367 pneumococcal isolates carried by
Massachusetts children (aged 3 months-7 years) collected during the winter of 2010–11 and used eBURST
software to compare the pneumococcal population structure with that found in previous years.
Results: One hundred and four distinct sequence types (STs) were found, including 24 that had not been
previously recorded. Comparison with a similar sample collected in 2009 revealed no significant overall difference
in the ST composition (p = 0.39, classification index). However, we describe clonal dynamics within the important
replacement serotypes 19A, 15B/C, and 6C, and clonal expansion of ST 433 and ST 432, which are respectively
serotype 22F and 21 clones.
Conclusions: While little overall change in serotypes or STs was evident, multiple changes in the frequency of
individual STs and or serotypes may plausibly be ascribed to the introduction of PCV-13. This 2011 sample
documents the initial impact of PCV-13 and will be important for comparison with future studies of the evolution
of the pneumococcal population in Massachusetts.
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MLSTBackground
The 7-valent pneumococcal conjugate vaccine (PCV-7),
which targeted seven pneumococcal serotypes (4, 6B, 9V,
14, 18C, 19F, and 23F), was introduced in 2000 to the
US childhood immunization schedule. Following the
introduction, substantial reductions in rates of invasive
pneumococcal disease (IPD) and asymptomatic carriage
caused by vaccine serotypes were observed [1,2]. How-
ever, increased carriage of pneumococci of non-vaccine
types (NVTs) was observed in the years that followed
PCV-7 introduction. This “serotype replacement” has* Correspondence: whanage@hsph.harvard.edu
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unless otherwise stated.been suggested to be a result of vaccine selective pres-
sure offering a relative advantage to non-vaccine types
[3]. Serotype 19A strains became a particular cause for
concern, being frequently isolated from IPD and often
resistant to multiple classes of antibiotics [4]. In 2010, a
13-valent pneumococcal conjugate vaccine (PCV-13)
was introduced for routine immunization of infants and
young children. In addition to the serotypes included in
PCV-7, PCV-13 targets 19A strains, as well as serotypes
1, 3, 5, 6A and 7F. It is hoped that PCV-13 will reduce
morbidity due to pneumococcal serotypes not included
in PCV-7 and, in particular, protect against IPD caused
by serotypes common in the developing world [5].
Previous work has probed the processes leading to the
emergence of NVTs during the PCV-7 era [6-8]. TheseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ously uncommon NVT lineages. In some cases, success-
ful strains that were originally of vaccine serotype
acquired a NVT capsule via homologous recombination
at the capsular locus, and these NVT variants have be-
come more frequent during the PCV-7 era [9-11]. The
replacement of the capsular locus through homologous
recombination is termed ‘serotype switching’. Much un-
certainty remains about the population level impact of
serotype switching and replacement on carriage and
invasive pneumococcal disease, in particular following
the introduction of PCV-13. To fully characterize the
pneumococcal population and to identify serotype
switching, multilocus sequence typing (MLST) can fur-
ther distinguish the background genotype of a particular
isolate [12]. MLST characterizes strains based on the
combination of alleles at seven housekeeping loci, which
together determine the sequence type (ST). STs can then
be used to characterize clones and their properties [13].
Serotype switching can be readily identified by the pres-
ence of isolates that share the same ST, but differ in
their capsule. MLST has been used previously to docu-
ment the origins of clones and to show that several im-
portant 19A strains were derived from vaccine serotype
ancestors via this mechanism [7,8].
We have previously collected community samples of
pneumococci from young children in Massachusetts in
2001, 2004, 2007, and 2009 and used MLST to deter-
mine the population structure and detailed molecular
epidemiology [6-8]. Here, we report the results of MLST
analyses of the 2011 samples, showing the further evolu-
tion of the pneumococcal population compared to sam-
ples from the same communities in 2009 [8]. While the
overall carriage prevalence did not change substantially
from 28.8% in 2009 to 31.5% in 2011, changes have
already been observed in the prevalence of vaccine
serotype carriage. Specifically, a substantial decline in
19A and the emergence of the interconverting 15B/C
as the most common serotype have been observed in
the early stages following the introduction of PCV-13
in Massachusetts [14]. These results will allow us to
compare future trends and changes in the pneumococ-
cal population with continued PCV13 use.
Methods
Data collection
Methods for sample collection and processing have been
previously described in detail [6-8]. Briefly, carried
pneumococcal strains were collected by nasopharyngeal
swabs between October 2010 and April 2011 from chil-
dren 3 months to 7 years of age attending pediatric and
family medicine practices for well-child or sick visits in
the same 8 Massachusetts communities as in our previ-
ous work [1,15,16], but with one additional site (BostonMedical Center) to include subjects residing in urban
Boston. Parental consent was obtained by study staff and
nasopharyngeal swabs were obtained by trained nurses.
All study procedures were approved by the Harvard
Pilgrim Health Care institutional review board. Samples
were processed for S. pneumoniae growth, antimicro-
bial susceptibility using E test, and serotype using the
Quellung reaction as previously described [16]. Stand-
ard Clinical and Laboratory Standards Institute (CLSI)
susceptibility cutoffs were used to classify organisms as
susceptible, intermediate, or resistant to the following
antibiotics: amoxicillin, benzylpenicillin, ceftriaxone, clinda-
mycin, erythromycin, levofloxacin, rifampin, trimethoprim-
sulfamethoxazole, and vancomycin [17]. Strains were
maintained as glycerol stocks at −80°C and DNA was
purified using DNeasy tissue kits (Qiagen, Valencia,
CA). To maintain consistency with our previous stud-
ies, we consider 15B and 15C to be a single, rapidly
interconverting serotype, 15B/C. The results from the
2010–2011 dataset were compared with 291 carriage
isolates collected from Massachusetts communities in
the 2008–2009 season, which have previously been de-
scribed in detail [8].
Multilocus sequence typing (MLST)
Sequence types (STs) of isolates were determined by
MLST as previously described [12]. Sequences of each of
the seven gene fragments used in the pneumococcal
MLST scheme were obtained from both DNA strands
with an ABI 3700 or ABI 3730xl DNA analyzer. The se-
quences were aligned and trimmed to defined start and
end positions using MEGA version 4 [18]. Allele and ST
assignments were made using the MLST website (spneu-
moniae.mlst.net). All alleles not already present in the
pneumococcal MLST database were verified by re-
sequencing the gene fragment on both strands. For STs
found among isolates of more than one serotype the
MLST loci were re-sequenced and serotypes were con-
firmed by Quellung reaction. Cases of serotype switching
were identified as isolates of the same ST (or with allelic
profiles differing at one of the seven MLST loci), but
which have different serotypes.
Analysis
Differences in the STcomposition of the 2009 and 2011 pop-
ulations were estimated using the classification index, with
significance assessed using a permutation method [6,19]. The
diversity of the samples was estimated using Simpson's index









where x is the fraction of the sample with sequence type i, m
is the total number of sequence types, and N is the sample
size. Variance and 95% confidence intervals were calcu-
lated as previously described [21].
Table 1 Serotypes associated with sequence types (ST)
found 4 or more times among 367 S. pneumoniae carriage
isolates in children 3 months - 7 years from Massachusetts
communities in 2010–2011
ST N (%) Serotypes (N)
199 35 (9.5) 15B/C (33), 19A (2)
62 21 (5.7) 11A (21)
320 19 (5.2) 19A (19)
433 16 (4.4) 22F (16)
63 14 (3.8) 15A (10), 15B/C (3), 19A (1)
558 14 (3.8) 35B (13), 29 (1)
338 13 (3.5) 23A (13)
432 12 (3.3) 21 (12)
180 10 (2.7) 3 (10)
498 10 (2.7) 35F (10)
695 8 (2.2) 19A (8)
3280 8 (2.2) 15B/C (8)
439 7 (1.9) 23B (7)
547 7 (1.9) 34 (7)
816 7 (1.9) 10A (7)
1390 7 (1.9) 6C (7)
138 6 (1.6) 6C (6)
659 6 (1.6) 16F (6)
162 5 (1.4) 15B/C (5)
7490 5 (1.4) 21 (5)
36 4 (1.1) 23B (4)
191 4 (1.1) 7F (4)
632 4 (1.1) 9N (4)
1262 4 (1.1) 15B/C (4)
1876 4 (1.1) 6C (3), 6A (1)
1924 4 (1.1) 17F (4)
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population structures in 2009 and 2011 [22]. This pro-
gram groups related STs sharing 6 of the 7 alleles into
clonal complexes (CCs), identifies the putative ancestor
of each CC, and outputs a graphical representation of
these relationships. This enabled us to assess the fre-
quency of CCs of related strains in the 2011 sample and
compare them with the sample collected in 2009 [8].
Fisher’s exact test was used to test for the significance of
changes in frequency of individual STs compared to all
other STs within each serotype. Analyses were per-
formed using SAS software version 9.3 (SAS Institute,
Cary NC) and R statistical package.
Results and discussion
ST diversity
In total, 367 S. pneumoniae carriage isolates were avail-
able for typing. We found 104 distinct STs, 24 of which
were new to the database and included several previ-
ously undocumented alleles (1 aroe, 4 gdh, 1 spi, 2 xpt,
and 3 ddl). Those STs present 4 or more times in the
sample, along with the serotypes associated with them,
are summarized in Table 1. Taken together, these 26 STs
make up 69% of the sample. The full results of all iso-
lates are presented in Additional file 1. The diversity (D)
of STs in the 2011 sample was 0.98 (95% CI: 0.97-0.99)
This is virtually identical to that of the 2009 sample in
which D was 0.98 (95% CI: 0.98-0.98), indicating no sig-
nificant change in ST diversity following the introduc-
tion of PCV-13 such as might be expected from the loss
of STs associated with vaccine serotype as observed fol-
lowing PCV-7 introduction [7,8,23]. This is consistent
with the previous hypothesis that the carried pneumo-
coccal population has reached a new equilibrium after
PCV-7 use [23].
We examined whether the 2009 and 2011 samples
were significantly different in their ST composition with
the classification index [19]. This test calculates a statis-
tic for the similarity between the ST content of two pop-
ulations, and then randomly permutes the pooled
populations into two samples of the same size to esti-
mate how the test statistic is distributed under the null
hypothesis of the two samples being from the same
population. We found no significant evidence of differ-
ence between the 2009 and 2011 samples (p = 0.39 from
1000 permutations). We also applied Fisher’s exact test
to assess difference in ST composition within each sero-
type and found no significant difference between the
2009 and the 2011 samples.
To allow for a broader comparison of the latest results
with those obtained in 2009, we also generated a com-
parative eBURST population snapshot, which grouped
STs into 28 clonal complexes (Figure 1). eBURST groups
related STs, represented as circles, into CCs andidentifies the probable ancestor (shown in blue) of each
CC as the ST with the largest number of minor differ-
ences. STs shown in green were only found in the 2011
dataset. STs in black were only found in the 2009 dataset.
Those in pink were found in both. As shown, all but one
of the CCs were identified in both samples, indicating that
that most common clones persisted in Massachusetts over
the examined time span. On a broader level, 13 of the 15
CCs identified using genomic data from samples between
2001 and 2007 [10] were identified in 2011; those that
were absent were the group of serotype 6A isolates of
CC376, and the unusual set of non-typable isolates highly
divergent from the rest of the population.
Changes within individual serotypes
Three serotypes are responsible for nearly half of the














Figure 1 Comparative eBURST diagram showing changes between the 2009 and 2011 S. pneumoniae carriage isolates in children 3
months - 7 years from Massachusetts communities. Each ST is represented by a point, the size of which is determined by the number of
isolates with that ST in the combined dataset. STs differing at a single MLST locus are shown linked by a straight line. A clonal complex (CC) is a
group of STs sharing 6 of 7 alleles with at least one other member of the group. STs which are the putative founders of their CC are shown in
blue, with those which are thought to have given rise to subgroups shown in yellow. Those STs which cannot be linked to any other in the
sample are termed singletons and appear as unlinked points. For more information see http://spneumoniae.mlst.net/eburst/. The ST numbers are
colored according to whether they were found only in 2009 (black), only in 2011 (green), or in both (pink).
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clonal composition of the most common serotypes in
the 2011 sample, histograms comparing the ST compos-
ition of serotypes 19A, 15B/C, and 6C in the 2009 and
2011 samples are shown in Figure 2. Using Fisher’s exact
test, no statistically significant differences were observed in
the ST populations within serotype 19A, 15B/C, and 6C.
Serotype 19A is of considerable concern as an import-
ant replacement serotype in carriage and invasive dis-
ease. It makes up 11% of the 2011 sample (41/367)
compared to 14% of the 2009 sample (42/291). In
addition, serotype 19A is represented by three predom-
inant STs: two ST 199 (4.9% of serotype 19A), nineteen
ST 320 (46.3% of serotype 19A), and eight ST 695
(19.5% of serotype 19A). Similar to the changes between
2007 and 2009, a decrease in ST 199 in 19A was ob-
served in parallel with slight increases in ST 320 and ST
695 as shown in Figure 2(a). As previously observed
and in contrast with ST 199, ST 695 has remained at a
relatively constant prevalence. We also observed that
ST 320 remains the most common ST for serotype
19A, making up almost half of the 19A population. ST
320 was found to be associated with high-levelbenzylpenicillin resistance (all isolates had minimum in-
hibitory concentrations ≥3 μg/mL), high-level erythro-
mycin resistance (all but two isolates with minimum
inhibitory concentrations >256 μg/mL) and high-level cef-
triaxone resistance (all isolates with minimum inhibitory
concentrations ≥2 μg/mL). The continued success of ST
320 may be determined by its high level of resistance to
multiple antibiotic classes, giving it an advantage over ST
199. Clonal replacement among 19A pneumococcal
population observed following PCV-7 has been dis-
cussed previously [8]. Serotype 19A will become in-
creasingly important for surveillance of pneumococcal
carriage and invasive disease given that serotype 19A is
included in PCV-13.
Serotype 15B/C represents 16% of the 2011 sample
(59/367), compared to 11% of the 2009 sample (33/291).
The increase in serotype 15B/C isolates represents the
combination of the stable prevalence of the 15B/C ST
199 isolates and the emergence of multiple unrelated
clones including ST 63, ST 1262, ST 3139, and ST 7484,
as shown in Figure 2(b). The most common ST in 15B/
C strains was ST 199 (55.9% of serotype 15B/C), as has












































































Figure 2 Changes between the 2009 and 2011 samples within individual serotypes (a) 19A (b) 15B/C and (c) 6C among S. pneumoniae
carriage isolates in children 3 months - 7 years from selected Massachusetts communities. Results for 2009 are shown in gray and 2011 in
black. STs are shown as the proportion of isolates within each serotype, arranged by clonal complex according to eBURST analysis. The ancestral ST of
each clonal complex in eBURST analysis is shown below the panel. Other indicates STs for which ancestry could not be determined by eBURST.
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3280 (13.6% of serotype 15B/C). Strains of this ST were
originally detected in a single community in 2007 exhi-
biting an intermediate level resistance to penicillin [10]but after rising to just over a quarter of serotype 15B/C
isolates in 2009, they do not appear to achieve more
widespread success. In addition, among other STs identi-
fied as 15B/C, we observed three ST 63 isolates (5.1% of
Chang et al. BMC Infectious Diseases  (2015) 15:68 Page 6 of 7serotype 15B/C) that were 15B/C, which suggests sero-
type switching from previous 15A strains. This is of
interest as the Pneumococcal Molecular Epidemiology
Network (PMEN) has recognized this as the Sweden15AST63
multidrug resistant clone [24,25].
Like the other serotypes, the 6C population is made
up of multiple unrelated STs. It makes up 9% of the
2011 sample (32/367), compared to 11% of the 2009
sample (32/291). As shown in Figure 2(c), we observed a
decrease in ST 1379 (9.4% of serotype 6C) and related
ST 1292 (3.1% of serotype 6C), as well as ST 1390
(21.9% of serotype 6C) and ST 1692 (9.4% of serotype
6C). In 2011, ST 138 made up 18.8% of the serotype 6C
population. While this is not a significant increase from
the 2009 sample in which it comprised 15.6% (5/32) of
serotype 6C isolates in 2009, this combination of sero-
type and ST was not found in our samples prior to 2007,
when a single isolate was recorded [7]. Historically asso-
ciated with a 6B capsule, ST 138 is an example of sero-
type switching. We anticipate that 6C carriage may
decrease in coming years as a result of cross protection
from the 6A component of the vaccine [26].
Other serotypes
The largest change in frequency between 2009 and 2011
was found for ST 180, a serotype 3 clone. Although
non-significant (p = 0.076, two-tailed Fisher’s Exact test),
the proportion of samples with this ST and serotype was
10/367 (2.72%) as shown in Table 1, an increase from
2/291 (0.69%) in 2009 [8]. This may be related to the
low immunoglobulin G response for serotype 3, in
comparison to the other additional 5 serotypes in-
cluded in PCV-13. Immunogenicity studies of PCV-13
in the United States have shown that following vaccin-
ation at ages 2, 4, and 6 months, 73.3% of subjects had
antibody titers against serotype 3 exceeding 0.35 μg/mL, a
reference concentration for assessment of vaccine efficacy
against IPD defined by the WHO [27,28]. Additional sur-
veillance will be needed to determine whether this in-
crease in serotype 3 continues with increased uptake of
PCV-13.
In addition to ST 180, we also observed a striking in-
crease in ST 432 and ST 433, which are associated with
the non-vaccine serotypes 21 and 22F, respectively. Al-
though statistically non-significant, ST 433 increased
from 8/291 (2.75%) to 16/367 (4.36%) while ST 432 in-
creased from 4/291 (1.37%) to 12/367 (3.27%). This is
likely a result of clonal expansion following vaccination
and the early stages of serotype replacement given that
serotypes 21 and 22F are not included in PCV-13. Sero-
type 22F isolates of ST 433 have become increasingly
prevalent as a cause of invasive pneumococcal disease in
Japan following implementation of PCV-7 [29], and pre-
vious work using data collected in Massachusetts hassuggested this serotype has a relatively high potential to
cause invasive disease (on par with 19A) [30]. It is pos-
sible that we may see some non-PCV13 serotypes in-
crease and others may emerge due to the selection
pressure, although it is difficult to predict the extent of
subsequent carriage and invasive disease replacement by
such serotypes.
As in previous samples [6-8], we document numerous
11A isolates of ST 62. While this lineage is plainly success-
ful, it has low invasive capacity and is not as yet associated
with antibiotic resistance [30]. Future surveillance will be
important to note if either of these factors change with
continued high prevalence of this strain.
One isolate was found to be non-typable. The MLST
of this isolate was closely related to ST 15, which was as-
sociated with serotype 14 prior to vaccination [31].
While it is not clear from the present data whether the
capsule has been fully lost or down-regulated [32], a
serotype 14 capsule would be targeted by the vaccine
and thus loss of capsule may be an adaptation.Conclusions
We have previously used MLST to characterize samples
of carried pneumococci from MA children collected in
2001, 2004, 2007, and 2009. The overall carriage preva-
lence did not change substantially from 28.8% in 2009
to 31.5% in 2011 [14]. In this paper, we report the re-
sults of the MLST analysis of the most recent sample
collected in 2011. The 2011 sample was not found to
be significantly different in terms of diversity as mea-
sured by Simpson’s D or in terms of overall ST compos-
ition (tested using the Classification Index [19]) from
the 2009 sample. This is consistent with previous find-
ings that serotype distribution has reached a new equi-
librium in the presence of PCV-7 where the diversity of
population structure of carried serotypes was similar to
that observed in the absence of vaccination [8,23].
While it could be considered surprising that there was
no change despite the introduction of PCV-13 in April
2010, it should be noted that the sample was collected
as the vaccine was being introduced. Furthermore,
while high levels of coverage in young infants were
achieved over a short period of time, there would have
been lower levels of coverage achieved for those over
one year of age in our sample. Thus, we would not yet
anticipate the full benefit of the direct protection and
herd effect from PCV-13 vaccination due to its slow
uptake, particularly among older children [14]. Subse-
quent sampling will be needed to study the further evo-
lution of the pneumococcal population, to document
clonal changes within serotypes and the emergence of
additional non-vaccine serotypes with the increased up-
take of PCV-13.
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